Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 11, 2006
- Takara Bio Discovers Potent Antitumor Activity of Kelp-derived Fucoidan
September 11, 2006
- Taisho Toyama Certifies 38 "Super MRs" in Field of Infectious Disease
September 11, 2006
- R&D NEWS IN BRIEF
September 11, 2006
- Ajinomoto, Sankyo Announce Agreement on Novel Diabetes Treatment
September 11, 2006
- DNA Chip Research Focuses on Chips for Prediction of Prognosis, Preoperative Diagnosis
September 11, 2006
- Korosho Drafting New Vision for the Pharmaceutical Industry
September 11, 2006
- Unapproved CO Monitor Recalled
September 11, 2006
- BUSINESS NEWS IN BRIEF
September 11, 2006
- MEDICAL DEVICE NEWS IN BRIEF
September 11, 2006
- SELF-MEDICATION NEWS IN BRIEF
September 11, 2006
- JPA Survey Shows Strong Impact of TV Commercials on Use of Generics
September 11, 2006
- Korosho's FY2007 Budget Request Totals \21.6 Trillion with Focus on Anti-Cancer Measures
September 11, 2006
- Medical Expenditure Rose 1.8% to \32.1 Tril. in FY2004
September 11, 2006
- METI's Draft Budget Request Earmarks \2.8 Bil. for Anticancer Measures
September 11, 2006
- Working Team Proposes 5 New Targets for Healthy Japan 21 Project
September 11, 2006
- CDFS Committee Recommends Approval of 4 Drugs Including Velcade
September 11, 2006
- Weight of Healthcare Business Continues to Increase at Philips
September 11, 2006
- Group to Review Reports on Drugs for Pediatric Use
September 11, 2006
- Korosho Considers Prescription Surveys for Pediatric Use of Drugs
September 11, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…